CytImmune Sciences is an emerging leader in cancer nanomedicine. It is a platform company with products of its own in development. CEO Saba explains the technology and why he is confident it will ultimately help patients. The company has a Phase II development collaboration with the National Cancer Institute, and is scaling up its manufacturing to be ready.
Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.